The Recall Desk
ModerateFDA (Drugs)·D-0025-2023·Announced 2022-11-09

Ranibizumab eye implant recalled for non-functioning delivery system

Genentech is recalling Susvimo ocular implants (452 units nationwide) due to manufacturing defects in the drug delivery system. A few patients have experienced non-functioning implants.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: FDA Class III recall of defective drug delivery implants with documented non-functioning units affecting a few patients. No illnesses or injuries have been reported. This fits the typical profile of a low-risk Class III recall.

Plain-English summary

Genentech Inc. is recalling Susvimo (ranibizumab injection, 100 mg/mL), an ocular implant distributed nationwide. The implant is designed to deliver anti-VEGF therapy directly into the eye for serious eye conditions. The recall involves 452 vials and implants with multiple lot numbers and expiration dates through April 2027.

The implants have a manufacturing defect affecting the delivery system that does not meet filed specifications. A few patients have experienced implants that do not function properly and fail to deliver medication as intended.

Patients who have received a Susvimo implant should contact their healthcare provider to determine whether they received a recalled unit and to discuss treatment options.

The recalled product

Product
SUSVIMO (RANIBIZUMAB)
Brand
SUSVIMO
Manufacturer
Genentech Inc
Hazard
  • implant-malfunction
  • manufacturing-defect

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (16)

  • Lot/Exp: a) 3499188
  • Exp 10/31/2022
  • Lot 3523071
  • Exp 6/30/2023
  • b) 3456735
  • Exp 10/23/2026
  • 3456737
  • Exp 10/29/2026
  • 3477671
  • Exp 10/31/2026
  • 3480781
  • Exp 12/19/2026
  • 3506526
  • Exp 02/25/2027
  • 3506531
  • Exp 04/15/2027

Distribution

Distributed nationwide across the United States.